Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

Share Price is delayed by 15 minutes
Get Live Data
5.80    -0.10 (-1.69%)
Bid:
5.70
Ask:
5.90
Spread: 0.20 (3.509%)
Market Cap: £14.92m
TEK Live PriceLast checked at - London Stock Exchange

Intraday TekCapital Share Chart

Executive Appointment

9 Oct 2018 07:00

RNS Number : 3377D
Tekcapital plc
09 October 2018
 

 

Tekcapital plc

 

("Tekcapital" or the "Company")

 

Executive Appointment

Tekcapital plc, (AIM: TEK) the UK intellectual property investment group focused on creating marketplace value from university technology, announces that Dr Mireya McKee has joined as Business Development Manager.

Mireya has over 17 years of research, technology transfer and innovation management experience. She completed a Ph. D. in biochemistry from the University of Texas-Austin as a CONACYT fellow. Afterwards, she carried out postdoctoral research in nanotechnology at Oxford University, where she received an EPSRC Developing Future Leaders-Women in Science grant.

She transitioned into business, completing a certification program on the commercialization of scientific research at Oxford's Saïd Business School. Dr McKee also served as a senior consultant in technology transfer for Oxford University Innovation (OUI).

Mireya founded an innovation management consultancy that provided training and support to universities and start-up companies around the globe. As part of this effort, she has become knowledgeable about the innovation ecosystems of Latin American countries where she has assisted a number of government agencies in designing and implementing innovation policies and programs.

Clifford M. Gross Ph.D., Chief Executive Officer of Tekcapital plc commented:

"We are enthusiastic to have Dr McKee join our team and we are confident she will help to expand our service business in Latin America."

For further information, please contact:

 

Tekcapital plc

Clifford M Gross, Ph.D.

 

Via Walbrook PR

finnCap Ltd (Nominated Adviser and Joint Broker)

 +44 (0) 20 7220 0500

Geoff Nash (Corporate Finance)

Max Bullen-Smith (Corporate Finance)

Camille Gochez (ECM)

 

Novum Securities (Joint Broker)

Colin Rowbury

 

+44 (0) 29 7399 9427

 

Walbrook PR Ltd

 +44 (0) 20 7933 8780

Paul Cornelius / Nick Rome / Sam Allen

 tekcapital@walbrookpr.com

 

Tekcapital plc - The World's Largest University Network for Open Innovation

Tekcapital's objective is to create value from investing in new, university-developed intellectual properties. Additionally, using its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a range of IP investment services to make it easy for organisations to find, evaluate, acquire and license university-developed technology. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAEVLFBVBFZFBX
Date   Source Headline
25th May 20227:00 amRNSPlacing to Raise £2 Million (c.US$ 2.5M)
6th May 202211:36 amRNSNotice of AGM
6th May 20227:00 amRNSFinal Year End Record Results
5th May 20227:00 amRNSGuident Update
3rd May 20228:35 amRNSGuident Update
19th Apr 20227:00 amRNSPortfolio Company Update - Guident
1st Apr 20227:00 amRNSPortfolio Company Update - Salarius
25th Mar 202211:39 amRNSNotification of Major Holdings
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
14th Feb 20227:00 amRNSSalarius Update
11th Feb 20225:58 pmRNSExercise of Stock Options and Total Voting Rights
11th Feb 20222:06 pmRNSSecond Price Monitoring Extn
11th Feb 20222:00 pmRNSPrice Monitoring Extension
11th Feb 202211:06 amRNSSecond Price Monitoring Extn
11th Feb 202211:01 amRNSPrice Monitoring Extension
4th Feb 20227:00 amRNSGuident Update
2nd Feb 20227:00 amRNSLucyd Expands Ecommerce Channels
4th Jan 20227:00 amRNSSalarius Completes Oversubscribed Crowdfund
29th Dec 20217:00 amRNSSalarius Appoints CEO
24th Dec 20217:00 amRNSSalarius Appoints Non Executive Director
14th Dec 20217:00 amRNSLucyd Filing for United States IPO
9th Dec 20217:00 amRNSSalarius Update
22nd Nov 202112:09 pmRNSHolding(s) in Company
16th Nov 20217:00 amRNSSalarius Update
15th Nov 20217:00 amRNSSalarius Update
11th Nov 20217:00 amRNSAppointment of new Auditor
4th Nov 20217:00 amRNSPortfolio Company Update: Lucyd Ltd ("Lucyd")
3rd Nov 20217:00 amRNSPlacing to raise £3.0 million
27th Oct 20217:00 amRNSSalarius Appointment of Chief Medical Officer
26th Oct 20214:40 pmRNSSecond Price Monitoring Extn
26th Oct 20214:35 pmRNSPrice Monitoring Extension
26th Oct 202111:05 amRNSSecond Price Monitoring Extn
26th Oct 202111:00 amRNSPrice Monitoring Extension
19th Oct 20218:00 amRNSLucyd Proposed IPO in the United States
19th Oct 20217:00 amRNSLucyd Update
14th Oct 202111:05 amRNSSecond Price Monitoring Extn
14th Oct 202111:00 amRNSPrice Monitoring Extension
14th Oct 20217:00 amRNSSalarius FDA Sodium Reduction Goals
8th Oct 20218:59 amRNSSaltMe Roll out in leading US Supermarket Chain
29th Sep 20212:17 pmRNSLucyd Distribution Growth
20th Sep 20214:41 pmRNSSecond Price Monitoring Extn
20th Sep 20214:36 pmRNSPrice Monitoring Extension
10th Sep 202111:30 amRNSNotification of Major Shareholding
31st Aug 20217:00 amRNSLucyd Update
24th Aug 20217:00 amRNSLucyd Non Executive Director Appointment
20th Aug 20219:05 amRNSSecond Price Monitoring Extn
20th Aug 20219:00 amRNSPrice Monitoring Extension
16th Aug 20217:00 amRNSRecord Half Year Results for period to 31 May 2021
5th Aug 20212:59 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.